Keyphrases
Active Treatment
33%
Best Response
33%
Bleeding Episodes
33%
Comorbidity
33%
Epithelial Phenotype
33%
Expectancy
33%
Group Stages
33%
Hematotoxicity
33%
Leukopenia
66%
Malignant Pleural Mesothelioma
100%
Number of Treatment
33%
Organ Function
33%
Overall Survival
33%
Partial Response
100%
Patients Included
33%
Pemetrexed
100%
Performance Status
66%
Poor Prognostic
33%
Progression-free Survival
33%
Progressive Disease
33%
Response Control
33%
Second-line Chemotherapy
33%
Thrombocytopenia
33%
Treatment Course
33%
Pharmacology, Toxicology and Pharmaceutical Science
Bleeding
33%
Comorbidity
33%
Diseases
100%
Leukopenia
66%
Mesothelioma
33%
Overall Survival
33%
Pemetrexed
100%
Pleura Mesothelioma
100%
Progression Free Survival
33%
Second-Line Chemotherapy
33%
Thrombocytopenia
33%